{filename}

Publications

Categories

Filter by Topics

ABC-DLBCL ADCC Gene Alteration Airway Remodeling AKT Targeted Therapy ALK Alleles Angiogenesis Anti-TNF Alpha Therapy Anus Apoptosis AR-Specific T Cells Asthma Autocrine Signaling Autoimmune Disorder AXL B-cell lines B-cell lymphoma Biofluid Biology of neoplasia Biomarker Biomarker Analysis Biomarker Discovery Biomarker Patient Stratification Biomarker Validation Biomarkers Biomarkers Outcome Bladder Bladder Cancer blood Brain Brain RNA Breast Breast Cancer Cancer Immune Response Carcinoma Cardio Vascular Disease cardiovascular disease CD-19 CD44 CDKN2A mutation Cell line Cells Cerebral Spinal Fluid Checkpoint Inhibitors Chemoresistance Chronic Obstructive Pulmonary Disease Circulating miRNAs Circulating Tumor Cells Classification Clinical Outcome Prediction Clinical Trials cMET Coccidioidomycosis Colon Colon cancer Colorectal cancer Comparative Approach Comparative Study Comparison study Comprehensive Gene Expression Study Cord Blood Buffy Coat Core Needle Biopsy Custom mRNA Cyclin E mRNA Cytokines Detection Developmental Immunotherapy Diabetes Diagnostic Biomarkers Differential Diagnosis Differential Expression Differential Gene Expression Analysis Diffuse large B-cell lymphoma Dissecting Genomic Biomarkers DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury Efficacy EGFR Muatations EMT EMT-mediated resistance Encephalophy Epidemiology outcomes Epigenetics Epigenomic Epstein-Barr ERBB2 Esophageal Cancer Exosomes Extracellular Vesicles Extracted RNA Fabry Disease Feasibility FFPE FFPE Canine Tumor FGF Ligand Trap FGFR Fibrous Tumors Gastrointestinal Cancers Gene Expression Analysis Gene Expression Comparisons Gene Expression Profiling Gene Expression Signatures Gene Fusions Gene Pathway Analysis Genetic Polymorphism Genomic Genomic Bioinformatics Head and Neck Cancer Heart HER2 Histone Deacetylase Inhibitors HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel Human Human serum Hypoxia Immune Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immune-checkpoint blockade Immune-related Colitis Immuno-Oncology Immunofluorescence Immunology Immunotherapy Induction Chemotherapy Inflammation Inflammatory Signatures Interferon Gamma Signature Invasive Breast Carcinoma Juvenile Arthritis Kidney Liposarcoma Liquid Biopsy Liver Lung Lung Adenocarcinoma Lung cancer Lung Carcinoma Lupus Lymph Node Metastasis Lymphoma Mechanism of Action Melanoma Mesothelioma MET Metastatic Colon Cancer Metastatic Prostate Cancer Methods Comparison Mice Mice PDX Microenvironment miRNA miRNA WTA miRQC study Molecular Characterization Mouse Mouse mRNA mRNA mRNA custom mRNA expression in tumors mTOR pathway mTORC1 mTORC2 Mucin Hypersecretion Multiple Myeloma Muscle Mutations MYC Myocardial Reperfusion Myocarditis NAFLD Nash and Fibrosis Natural Killer Cells Neoantigens Neuroendocrine Tumor Nivolumab non-Hodgkin Lymphoma Non-small Cell Lung Cancer Novel Therapeutic Targets NSCLC NTRK1 Oesophageal Adenocarcinoma Oncogenes Oncology Oncomirs Oral Cancer Oral Squamous Cell Carcinoma Osteoclast Ovarian cancer Overexpression P13KmTOR Inhibitor Palbociclib Pancreas Pancreatic Cancer Pancreatic ductal adenocarcinoma Pancreatic Ductal Adenocarcinoma Paralysis Parkinson's Disease Pathogenesis Pathology Pathway Analysis Pathways PCA Cell Lines PD-1 Pd-L1 PD-L1 Phase 3 clinical trial PI3K signaling pathway PIK3CA mutation Plasma plasma Platform Comparison Pralatrexate predictive Predictive Biomarkers Predictive Modeling Pro-inflammatory cytokines Profiling Profiling Signature Development Prognostic Prognostic Biomarkers Programmed cell death protein 1 Programmed death ligand 1 Progression free-survival Prostate Prostate Cancer qNPA qPCR Radiation Toxicities Radioimmunotherapy Rearrangements rectum Regulation Renal Cell Carcinoma Renal Disease Responders vs Non-responders Response rate RET Reveal Rheumatoid Arthritis Risk Score Rituximab ROS1 safety Sarcoidosis Sarcoma SCBC SCLC Serum Signaling Inhibitors Signaling Pathways Signature Development Signature Pathway Analysis Signature Validation Signatures Sinonasal Undifferentiated Carcinoma Skin Small bowel Small cell bladder cancer Small Cell Bladder Cancer Small Cell Lung Cancer SPECS Lung Consortium Squamous cell carcinoma Sub-typing Surveillance Survival Outcomes Survival plots Synovial Fluid System Validation Systemic Lupus Erythematousus T cell T-cells Technology Comparison Therapeutic Response Therapeutic targets Tissue-based biomarkers TMB Toxicity TP53 mutation Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Triple Negative Breast Cancer Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes Tumor Mutational Burden tumor mutational burden Type 1 diabetes Urothelial carcinoma Uveal melanoma VEGFR Venetoclas Vistusertib WNT Path Signaling Xenograft Tissue

New tools for Biomarker Discovery Promise Personalized Treatment for Rheumatoid Arthritis

This webinar will outline an ongoing project to develop personalized treatment strategies for rheumatoid arthritis patients using miRNA profiling. 

Millions of patients with rheumatoid arthritis are treated with TNF-α inhibiting agents, but the response rate to these therapies is low (30 percent to 40 percent) and no tool exists to predict the treatment response.

In the study that will be discussed in this webinar, Dr. Eric Schordan, Head of the Molecular Diagnostic Department at Firalis and TcLand Expression, led a project that aimed to address this via miRNA profiling in RA patients.

Using the HTG EdgeSeq platform, Dr. Schordan and colleagues first identified sets of miRNAs that discriminate responders from non-responders to anti TNF-α therapy and then developed a panel called RABIOPRED that includes more than 2,100 mRNAs identified as predictors of anti TNF-α therapy.

In a study that enrolled 67 RA patients, Dr. Schordan and his team determined that miRNA profiling using the HTG EdgeSeq platform served as a useful tool for biomarker discovery and enabled them to build predictive models for response to anti-TNF-α drugs. 

In this webinar, Dr. Schordan will discuss the details of that study, as well as his team's plans to validate the panel in a multicentric prospective clinical study of 600 patients.

Speaker

Eric Schordan
Head of the Molecular Diagnostic Department at Firalis and TcLand Expression.

Speaker Biography

Eric received his PhD in molecular and cellular biology from University Louis Pasteur, Strasbourg, in 2005. After his PhD, he held a postdoctoral position at the University of Heidelberg with the support of an IEF Marie-Currie fellowship and a position of researcher at the University Medical Center Greifswald in the field of molecular and cellular biology. He was selected in 2007 for the participation to the 57th Meeting of Nobel Laureates in Lindau. In 2013 he joined Firalis to create the department of Molecular Diagnostics for the discovery, validation and qualification of nucleic biomarkers.

Return To List